Tracey Roizman

A recent systematic review and meta-analysis reveals the promising efficacy and safety of combining compound glycyrrhizin with second-generation non-sedating antihistamines in treating chronic urticaria, offering a potential advancement in dermatological therapy. This innovative approach may redefine chronic urticaria management, providing new options for patients seeking more effective treatments. Compound glycyrrhizin combined with second-generation non-sedating antihistamines...

A recent observational study delved into the long-term treatment of solar urticaria, focusing on the role of omalizumab. It reveals key findings on therapeutic outcomes and response predictors, which may provide insights for the management of the condition in clinical practice.  Solar urticaria patients show a significant response to omalizumab treatment. FcεRI level is a...

Insights were gathered from a worldwide survey conducted among allergists/immunologists, revealing prescribing patterns, challenges, and effectiveness of omalizumab in treating chronic spontaneous urticaria. The study highlights the need for novel therapies and the importance of understanding global prescription trends. Omalizumab, an FDA-approved biologic for chronic spontaneous urticaria, is widely prescribed but faces global challenges in...

A recent retrospective analysis reveals that ixekizumab-induced urticaria in psoriasis patients is associated with a shorter duration of remission, suggesting a role of mast cell activation in this process. The findings emphasize the need for targeted management strategies for patients exhibiting these adverse reactions. Ixekizumab treatment in psoriasis patients may lead to urticaria and early...

A recent systematic review has uncovered disparities in clinical trial participant demographics and outcome reporting for H1-antihistamine-refractory chronic spontaneous urticaria. This analysis reveals a need for more diverse representation and standardized outcome measures in clinical trials for this condition. The review included 23 randomized clinical trials involving 2480 participants, highlighting a global increase in trials...

Patients shifting from an oral regimen to injectable cabotegravir plus rilpivirine demonstrated a significant improvement in total cholesterol/high-density lipoprotein cholesterol in a recent retrospective cohort study; however, there were no significant changes in inflammatory biomarkers. Long-acting cabotegravir plus rilpivirine, administered via injection into the gluteus muscle, has a higher satisfaction rate compared to antiretroviral therapy...

C-reactive protein is negatively correlated with high-density lipoprotein in patients with dry age-related macular degeneration and may serve as an early disease predictor, according to the results of a retrospective study. The development of age-related macular degeneration (AMD) is associated with several risk factors, such as abnormal levels of lipid analytes, the patient’s age, and...

First-trimester dyslipidemia in pregnant women with subclinical hypothyroidism is associated with an increased risk of adverse pregnancy outcomes, according to a recent cohort study. Subclinical hypothyroidism is associated with dyslipidemia and may have adverse pregnancy outcomes. This thyroid disorder is common during pregnancy, increasing the risk for small for gestational age infants, preterm birth, and...

High lipoprotein-associated phospholipase A2 activity is associated with an increased risk for cardiovascular death and major adverse cardiovascular events in patients undergoing maintenance hemodialysis, facilitating the identification of patients at a greater cardiovascular mortality risk, according to the results of a recent prospective cohort study. Dyslipidemia is a common complication among chronic kidney disease patients...